Aims and objectives
Clinical trials require the consistent reporting of tumor metrics by radiologists.
A study performed at the MD Anderson Cancer Center and reported at the ECR 2014 indicated that radiologists only mentioned 36% of baseline lesions in follow up reports .
To improve this process,
we developed a mutlimedia structured reporting system,
to automate clinical trial management and analysis using structured data.
Methods and materials
The ViSion reporting system records keyimages,
disease metrics and a radiologist’s descriptions of image findings during his/her analysis of oncologicalimaging studies and assembles the data in a multimedia report .
The system provides a means to link imagefindings from serial examinations to generate disease timelines that graphically illustrate progression of disease atindividual anatomical sites.
Certain image findings can be designated as “target lesions” from which the calculation ofResponse Evaluation Criteria in Solid Tumors (RECIST) is automated .
the ViSion system aggregatesstructured data from...
The ViSion system has been employed in three IRB-approved clinical trials at a major cancer center,
andits use has improved the efficiency of radiological data collection for tumor assessments and clinical trial analyses.
Multimedia structured reporting provides a means to automate and improve the efficiency of clinicaltrial management and analysis,
thereby potentially reducing the costs of developing new therapies.
allowing patients to identify clinical trials for which they qualify may increase participation in those studies.
David Vining is the CEO and Founder of VisionSR,
which has licensed the ViSion technology from the University of Texas MD Anderson Cancer Center.
and Cristi Popovici are employees of Eloquentix,
Discontinuity in radiology reporting of serial examinations for tumour response assessment.
Accessed January 12,
A ViSion to transform the practice of structured reporting.
Spectrum 2013;20: 23-25.
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).
European Journal of Cancer.
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used,